News | September 13, 2021
Boehringer Ingelheim and Twist Bioscience ink antibody discovery collaboration
Research collaboration covers multiple antibody research programs
Research collaboration covers multiple antibody research programs
HTL will build, validate and operate a botulinum manufacturing facility in the US
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
In March it launched its first plastic-free toothbrush packaging, which included Sensodyne Pronamel and parodontax brushes in the US. Asia Pacific rollout of this commenced in Australia
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
At present 18 per cent of the local pharmaceutical market is under government's price control
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
Subscribe To Our Newsletter & Stay Updated
